Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension

Abstract

The objective of this study was to compare quality of life and incidence of dry persistent cough among patients treated with eprosartan and enalapril for mild-moderate hypertension. This was a randomised 26-week doubleblind controlled trial carried out in clinics in nine countries of North America, Europe and South Africa. A total of 529 patients aged 18 and over with diastolic blood pressure between 95 mm Hg and 114 mm Hg were studied. Treatment comprised of eprosartan or enalapril monotherapy for 12 weeks with the option of hydrochlorothiazide addition for the remaining 14 weeks. The primary outcome measures were cough and the Psychological General Wellbeing Index (PGWB) total and subscales (anxiety, self-control, depression, general health, positive wellbeing and vitality). The results

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

“…Estimates suggest that around 10% of patients develop cough with ACE inhibitor therapy, and that it may lead to treatment withdrawal in approximately half of these patients [27,28]. The occurrence of ACE inhibitor-induced cough may impact on patient quality of life [28], although some studies suggest that it has little effect on patient well being [29,30]. Headache was more frequent with aliskiren than ramipril therapy, although the proportion of events considered to be related to study medication was low and similar in the two groups.…”

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

“…16 In the present study, we have shown than eprosartan alone or in combination with a diuretic can be effective in reducing SBP in elderly patients with ISH. While a cost analysis is beyond the purview of this manuscript, the lack of persistent cough (as seen with ACE inhibitors), 18 lack of drug interaction, 19 and once-a-day dosing, are additional benefits of eprosartan use. For patients who do not respond to eprosartan alone, the simple addition of a diuretic may be additive and suffice to decrease SBP levels.…”

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension

“…Only 9 studies, described in 13 publications (27,29,31,38,41,44,46,48,49,59,62,65,79), reported how many patients died or had myocardial infarction or stroke ( Table 2). Most of these studies excluded patients with clinically significant cardiovascular disease and other comorbid conditions.…”

“…Four fair-quality studies described in 8 papers reported quality-of-life outcomes (27, 31,35,38,41,43,48,76). They used a variety of quality-of-life scales.…”